GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. In early 2024, the Big Pharma debuted a pair of unbranded shorts entitled “Big ...

For Evangeline Lilly, the road to recovery doesn't have to be lonely. The Golden Globe-nominated actress, who has been navigating a traumatic brain injury, opened up about her recovery efforts in an ...

Jan 28 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and ...

Evangeline Lilly is opening up about her costly treatment following a traumatic brain injury. “I have spent a lot of money getting evaluated and getting targeted, expert advice on how to heal my brain ...

Commenting on reports that Eli Lilly (LLY) has approached the French government to acquire Abivax (ABVX), Marc de Garidel, CEO of the Paris-based biotech, denied that such a discussion took place, ...

Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC ...

I have written only two articles on LLY stock, the latest published in August 2025 with a "Buy" rating, which could have delivered 37-38% in total returns for buyers. While it looks a bit too ...

Eli Lilly's oral GLP-1 candidate, orforglipron, won't earn approval as fast as the company expected. Meanwhile, a notable competitor is making headway in this market. Even with this setback, Eli Lilly ...

NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly (LLY.N), opens new tab may take over his ...

Feb 4 (Reuters) - Eli Lilly forecast strong profit growth for 2026 on Wednesday on the back of surging obesity drug demand, shaking off pricing pressures that sank rival Novo Nordisk's outlook a day ...

Eli Lilly (LLY) reported better than expected earnings for the second quarter Thursday. But disappointing results of its much-awaited oral pill GLP-1 sent its stock down in early trading. The stock is ...